Incyte's Phase 3 Retifanlimab Anal Cancer Trial Listed as Completed
The POD1UM-303/InterAACT 2 study of retifanlimab added to carboplatin-paclitaxel in advanced anal cancer now carries COMPLETED status on ClinicalTrials.gov.
Read more
NETLIST Loses Three Federal Circuit Appeals Against Micron on Same Day
The Federal Circuit affirmed PTAB rulings invalidating claims of five Netlist memory patents challenged by Micron, including one precedential decision.
POLESTAR Posts $842M Half-Year Loss as Revenue Slips 4.4%
The EV maker cut its net loss by 29% in H1 2026, but adjusted EBITDA worsened to a loss of $521 million while deliveries were roughly flat.
CAMPBELL'S Cuts Dividend 36% and Guides FY27 EPS Down as Much as 24%
Q4 adjusted EPS fell 37% to $0.39, the quarterly payout drops to $0.25, and Campbell's targets $500 million in cost savings by fiscal 2030.
CIENA Revenue Jumps 37% to $1.67B as AI Drives Optical Demand
Ciena posted record fiscal Q3 revenue of $1.67 billion and adjusted EPS of $2.11, and raised its full-year revenue outlook to $6.42 billion.